within Pharmacolibrary.Drugs.ATC.G;

model G04CA54
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 5.833333333333333e-05,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg â†’ kg
    adminCount     = 1,
    Vd             = 0.034,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00046666666666666666,
    Tlag           = 2400,            
    Vdp             = 0.03,
    k12             = 25,
    k21             = 25
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G04CA54</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tamsulosin and tadalafil is a fixed-dose combination used primarily in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in adult men, with tamsulosin acting as an alpha-1 adrenergic antagonist and tadalafil as a phosphodiesterase-5 inhibitor. The combination is approved and used today for such indications in some countries.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models providing compartmental parameters for the tamsulosin and tadalafil fixed-dose combination exist as of June 2024. Therefore, estimated parameters are based on known pharmacokinetics of individual oral tamsulosin and tadalafil in healthy adult males.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G04CA54;
